Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

The effect of thiazolidinediones on BMD and osteoporosis

An Erratum to this article was published on 30 September 2008

Abstract

Thiazolidinediones, also known as glitazones, are insulin-sensitizing medications that account for approximately 21% of oral antihyperglycemic drugs used in the US. Although the main therapeutic effects occur in adipose tissue, muscles and the liver, studies suggest effects in bone as well. Currently, two thiazolidinediones are marketed in the US—rosiglitazone and pioglitazone—and several others are under investigation. This Review examines the evidence regarding the effects of thiazolidinediones on skeletal health. These drugs appear to trigger preferential differentiation of mesenchymal stem cells into adipocytes rather than osteoblasts, leading to decreased bone formation and increased adipogenesis. Although only a few small, randomized studies have examined the effects of thiazolidinediones on bone in humans, the available data suggest that these agents contribute to bone loss in postmenopausal women; the relationship is less clear in men. On the basis of this limited evidence, the absolute increase in fracture risk associated with thiazolidinediones seems to be small. Pending data from future randomized, controlled trials of the association between thiazolidinediones and low bone mass, prescribers should consider use of these drugs as a risk factor for the development of osteoporosis in postmenopausal women.

Key Points

  • Thiazolidinediones trigger preferential differentiation of mesenchymal stem cells into adipocytes rather than osteoblasts, leading to decreased bone formation and increased adipogenesis

  • Available evidence from clinical trials suggests that decreases in BMD are most notable in postmenopausal women taking thiazolidinediones

  • Clinicians should monitor BMD and other risk factors for osteoporosis during thiazolidinedione therapy

  • Osteoporosis therapy should be initiated in individuals who appear to be at increased risk of fracture, investigated by assessment of clinical risk factors and BMD testing

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Putative mechanisms of thiazolidinedione action on bone.

Similar content being viewed by others

References

  1. Centers for Disease Control and Prevention (online 6 April 2007) Number (in millions) of persons with diagnosed diabetes, United States, 1980–2005 [http://www.cdc.gov/diabetes/statistics/prev/national/tablepersons.htm] (accessed 25 June 2008)

  2. Rahman S et al. (2007) Effect of rosiglitazone/ramipril on preclinical vasculopathy in newly diagnosed, untreated diabetes and IGT patients: 1-year randomized, double-blind, placebo-controlled study. Eur J Clin Pharmacol 63:733–741

    Article  CAS  Google Scholar 

  3. Yokoyama J et al. (2007) Efficacy and safety of low-dose pioglitazone after primary coronary angioplasty with the use of bare metal stent in patients with acute myocardial infarction and with type 2 diabetes mellitus or impaired glucose tolerance. Heart Vessels 22: 146–151

    Article  Google Scholar 

  4. Eguchi K et al. (2007) Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes. Hypertens Res 30: 23–30

    Article  CAS  Google Scholar 

  5. Dunaif A (2008) Drug insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome—a reappraisal. Nat Clin Pract Endocrinol Metab 4: 272–283

    Article  CAS  Google Scholar 

  6. Glintborg D et al. (2008) Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment. Diabetes Care 31: 328–334

    Article  CAS  Google Scholar 

  7. Froment P and Touraine P (2006) Thiazolidinediones and fertility in polycystic ovary syndrome (PCOS). PPAR Res 2006: 73986

    Article  Google Scholar 

  8. Yki-Jarvinen H (2005) The PROactive study: some answers, many questions. Lancet 366: 1241–1242

    Article  Google Scholar 

  9. Grey A et al. (2007) The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 92: 1305–1310

    Article  CAS  Google Scholar 

  10. Soroceanu MA et al. (2004) Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol 183: 203–216

    Article  CAS  Google Scholar 

  11. Ali AA et al. (2005) Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 146: 1226–1235

    Article  CAS  Google Scholar 

  12. Okazaki R et al. (1999) Short-term treatment with troglitazone decreases bone turnover in patients with type 2 diabetes mellitus. Endocr J 46: 795–801

    Article  CAS  Google Scholar 

  13. Vestergaard P (2007) Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis. Osteoporos Int 18: 427–444

    Article  CAS  Google Scholar 

  14. Holmberg AH et al. (2005) Risk factors for hip fractures in a middle-aged population: a study of 33,000 men and women. Osteoporos Int 16: 2185–2194

    Article  Google Scholar 

  15. Forsen L et al. (1999) Diabetes mellitus and the incidence of hip fracture: results from the Nord-Trondelag Health Survey. Diabetologia 42: 920–925

    Article  CAS  Google Scholar 

  16. Schwartz AV et al. (2001) Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab 86: 32–38

    Article  CAS  Google Scholar 

  17. Nicodemus KK and Folsom AR (2001) Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care 24: 1192–1197

    Article  CAS  Google Scholar 

  18. Ottenbacher KJ et al. (2002) Diabetes mellitus as a risk factor for hip fracture in mexican american older adults. J Gerontol A Biol Sci Med Sci 57: M648–M653

    Article  Google Scholar 

  19. Ahmed LA et al. (2006) Diabetes mellitus and the risk of non-vertebral fractures: the Tromso study. Osteoporos Int 17: 495–500

    Article  Google Scholar 

  20. de Liefde II et al. (2005) Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. Osteoporos Int 16: 1713–1720

    Article  CAS  Google Scholar 

  21. Strotmeyer ES et al. Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study. Arch Intern Med 165: 1612–1617

    Article  Google Scholar 

  22. Schwartz AV et al. (2005) Diabetes and bone loss at the hip in older black and white adults. J Bone Miner Res 20: 596–603

    Article  Google Scholar 

  23. Schwartz AV et al. (2002) Older women with diabetes have a higher risk of falls: a prospective study. Diabetes Care 25: 1749–1754

    Article  Google Scholar 

  24. Vestergaard P et al. (2005) Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 48: 1292–1299

    Article  CAS  Google Scholar 

  25. Khan E and Abu-Amer Y (2003) Activation of peroxisome proliferator-activated receptor-gamma inhibits differentiation of preosteoblasts. J Lab Clin Med 142: 29–34

    Article  CAS  Google Scholar 

  26. Lecka-Czernik B et al. (1999) Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma2. J Cell Biochem 74: 357–371

    Article  CAS  Google Scholar 

  27. Kletzien RF et al. (1992) Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Mol Pharmacol 41: 393–398

    CAS  PubMed  Google Scholar 

  28. Mbalaviele G et al. (2000) Activation of peroxisome proliferator-activated receptor-gamma pathway inhibits osteoclast differentiation. J Biol Chem 275: 14388–14393

    Article  CAS  Google Scholar 

  29. Okazaki R et al. (1999) Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro. Endocrinology 140: 5060–5065

    Article  CAS  Google Scholar 

  30. Odegaard JI et al. (2007) Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 447: 1116–1120

    Article  CAS  Google Scholar 

  31. Watanabe S et al. (2003) Decrease in serum leptin by troglitazone is associated with preventing bone loss in type 2 diabetic patients. J Bone Miner Metab 21: 166–171

    Article  CAS  Google Scholar 

  32. Cornish J et al. (2002) Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. J Endocrinol 175: 405–415

    Article  CAS  Google Scholar 

  33. Cornish J et al. (1998) Systemic administration of amylin increases bone mass, linear growth, and adiposity in adult male mice. Am J Physiol 275: E694–699

    CAS  PubMed  Google Scholar 

  34. Cornish J et al. (1996) Insulin increases histomorphometric indices of bone formation in vivo. Calcif Tissue Int 59: 492–495

    Article  CAS  Google Scholar 

  35. Lecka-Czernik B et al. (2007) Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo. Endocrinology 148: 903–911

    Article  CAS  Google Scholar 

  36. Rubin GL et al. (2000) Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy. Cancer Res 60: 1604–1608

    CAS  PubMed  Google Scholar 

  37. Rzonca SO et al. (2004) Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145: 401–406

    Article  CAS  Google Scholar 

  38. Lazarenko OP et al. (2007) Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 148: 2669–2680

    Article  CAS  Google Scholar 

  39. Sottile VK et al. (2004) Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone). Calcif Tissue Int 75: 329–337

    Article  CAS  Google Scholar 

  40. Schwartz AV et al. (2006) Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 91: 3349–3354

    Article  CAS  Google Scholar 

  41. Berberoglu Z et al. (2007) Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women. J Clin Endocrinol Metab 92: 3523–3530

    Article  CAS  Google Scholar 

  42. Lecka-Czernik B et al. (2002) Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 143: 2376–2384

    Article  CAS  Google Scholar 

  43. FDA (2000) Withdrawal of troglitazone and cisapri. JAMA 283: 2228

  44. Schwartz AV (2006) Diabetes, TZDs, and bone: a review of the clinical evidence. PPAR Res 2006: 24502

    Article  Google Scholar 

  45. Yaturu SB et al. (2007) Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men. Diabetes Care 30: 1574–1576

    Article  CAS  Google Scholar 

  46. Kahn SE et al. (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355: 2427–2443

    Article  CAS  Google Scholar 

  47. Sanders KM et al. (1999) Age- and gender-specific rate of fractures in Australia: a population-based study. Osteoporos Int 10: 240–247

    Article  CAS  Google Scholar 

  48. [No authors listed] (2007) Observation of an increased incidence of fractures in female patients who received long-term treatment with ACTOS (pioglitazone HCl) tablets for type 2 diabetes mellitus. Deerfield, IL: Takeda

  49. Li M et al. (2006) Surface-specific effects of a PPARgamma agonist, darglitazone, on bone in mice. Bone 39: 796–806

    Article  CAS  Google Scholar 

  50. Lazarenko OP et al. (2006) Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat. Bone 38: 74–84

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kenneth G Saag.

Ethics declarations

Competing interests

RS Rosenthal has acted as a consultant or received honoraria from Bristol Myers/Sanofi, Daiichi Sankyo, GlaxoSmithKline, Merck and Novo Nordisk. KG Saag has received grants or research support from Amgen, Eli Lilly, Merck and Novartis. He has also acted as a consultant or received honoraria from Proctor & Gamble. The other authors declared no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

McDonough, A., Rosenthal, R., Cao, X. et al. The effect of thiazolidinediones on BMD and osteoporosis. Nat Rev Endocrinol 4, 507–513 (2008). https://doi.org/10.1038/ncpendmet0920

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0920

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing